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Myeloid-derived-suppression cells (MDSCs) are believed
to be an important immune evasion mechanism by sup-
pressing T cells. We investigated whether MDSCs have
direct T cell independent pro-carcinogenic effect on
tumor cells. We sorted the monocytic CD14+/CD11b
+/HLA-DRlow MDSCs from head and neck squamous cell
carcinoma (HNSCC) patients and found that MDSCs
increased the proliferation index of HNSCC cells. Similar
results were seen from co-culturing murine MDSCs and
CT26 and B16 cells. Supernatant from the MDSCs were
found to secrete inflammasome cytokines IL-1b and
IL-18. MDSC’s enhancement of proliferative index of the
tumor was found to be caspase-1 dependent using
FLICA. To test this in vivo, T cell depleted caspase-1 null
mice showed significant decrease in tumor growth rate.
To confirm the importance of myeloid inflammasome
signaling in carcinogenesis, we suppressed MyD88 gene
in tumor cell line Cal27 and found that the ability of
MDSCs to promoting tumor proliferation is diminished.
Taken together, our findings demonstrate that MDSCs
can promote tumor cells proliferation on a inflamma-
some cytokines dependent manner.
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